Sernova (TSX: SVA) (OTCQB: SEOVF) is a clinical-stage biotechnology company that is advancing a novel cell therapy platform for the treatment of chronic diseases. Our lead program is evaluating our Cell Pouch System™ as a potential ‘functional cure’ for insulin-dependent diabetes. In addition, we have a robust pipeline that includes preclinical programs in hemophilia A and hypothyroidism. Learn more on our website: https://www.sernova.com/.